Insider Transactions in Q1 2026 at An2 Therapeutics, Inc. (ANTX)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 12
2026
|
Gilbert Lynn Marks |
BUY
Grant, award, or other acquisition
|
Direct |
11,560
+13.31%
|
-
|
|
Jan 12
2026
|
Patricia A. Martin |
BUY
Grant, award, or other acquisition
|
Direct |
3,650
+17.76%
|
-
|
|
Jan 12
2026
|
Kabeer Aziz |
BUY
Grant, award, or other acquisition
|
Direct |
11,560
+18.05%
|
-
|
|
Jan 06
2026
|
Stephen David Prior Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,858
-4.61%
|
$2,858
$1.01 P/Share
|
|
Jan 06
2026
|
Lucy Day Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,512
-6.82%
|
$5,512
$1.01 P/Share
|
|
Jan 06
2026
|
Joshua M Eizen |
SELL
Open market or private sale
|
Direct |
6,931
-4.35%
|
$6,931
$1.01 P/Share
|
|
Jan 06
2026
|
Sanjay Chanda Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,956
-7.28%
|
$5,956
$1.01 P/Share
|
|
Jan 05
2026
|
Stephen David Prior Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
3,604
-5.5%
|
$3,604
$1.0 P/Share
|
|
Jan 05
2026
|
Lucy Day Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,295
-3.91%
|
$3,295
$1.0 P/Share
|
|
Jan 05
2026
|
Joshua M Eizen |
SELL
Open market or private sale
|
Direct |
17,923
-10.11%
|
$17,923
$1.0 P/Share
|
|
Jan 05
2026
|
Sanjay Chanda Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,295
-3.87%
|
$3,295
$1.0 P/Share
|